Deep Vein Thrombosis News and Research

RSS

Deep vein thrombosis, or DVT, is a blood clot that forms in a vein deep in the body. Most deep vein clots occur in the lower leg or thigh. If the vein swells, the condition is called thrombophlebitis. A deep vein thrombosis can break loose and cause a serious problem in the lung, called a pulmonary embolism, or a heart attack or stroke.

Study suggests strategies to bolster the administration of clot-busting drugs

Venous thromboembolism (VTE) is a potentially deadly condition in which a blood clot (known as a deep vein thrombosis [DVT]) forms in the deep veins of the leg, groin or arm and may dislodge.

1 Sep 2022

What is the association between COVID-19 and thrombotic events?

In a new study, researchers assessed the association of COVID-19 and influenza with thrombotic events among patients.

18 Aug 2022

French study on cardiovascular disease incidence during COVID pandemic and vaccination campaign

Researchers describe failures of the French healthcare system as reflected by increased hospitalizations due to certain acute cardiovascular diseases in 2021.

7 Aug 2022

Researchers delve deeper into the structure of protein receptor crucial for cardiovascular health

5 Aug 2022

Higher suPAR levels linked with increased risk of blood clot formation

Blood clots are thought to occur in as many as a third of patients hospitalized with COVID-19. In many cases these clots can be deadly, such as pulmonary embolisms-;blood clots that travel to the lungs. In fact, in nearly one third of patients with COVID-19, these clots led to death.

4 Aug 2022

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

With this approval, RINVOQ® is the first and only Janus Kinase inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in the EU.

From AbbVie 29 Jul 2022

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

AbbVie today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of upadacitinib (RINVOQ® 15 mg, once daily) for the treatment of active non-radiographic axial spondyloarthritis (nr‑axSpA) in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).*

27 Jun 2022

Low-dose apixaban treatment reduces recurrence of venous thromboembolism compared to anticoagulant discontinuation after negative D-dimer

Patients who have suffered from a first episode of unprovoked venous thromboembolism (VTE) have an eight times higher risk of recurrence if they stop treatment after repeated negative D-dimer tests, instead of continuing with low-dose anticoagulant (apixaban).

20 May 2022

Incidence of arterial and venous thromboembolism and death in COVID-19 patients

Researchers estimated the incidence of arterial or venous thrombosis in patients with coronavirus disease 2019.

19 May 2022

Maternity Disparities Taskforce focuses on supporting women’s health before and during pregnancy

Minister for Women's Health Minister Maria Caulfield and Chief Midwifery Officer Professor Jacqueline Dunkley-Bent co-chaired the second meeting of the Maternity Disparities Taskforce this week (Monday 16 May 2022).

18 May 2022

Many treatments for intracerebral hemorrhage are not as effective as previously thought, guideline suggests

Some treatments or preventive therapies used to manage intracerebral hemorrhages (ICH), or a bleeding stroke, are not as effective as previously believed, according to the new American Heart Association/American Stroke Association guideline for caring for people with spontaneous ICH, published today in the Association's Stroke journal.

17 May 2022

UNC researcher working with NASA to study blood clot formation in astronauts during space missions

Are astronauts more likely to develop blood clots during space missions due to zero gravity? That's the question NASA is trying to answer with help from UNC School of Medicine's Stephan Moll, MD, professor in the UNC Department of Medicine.

3 May 2022

Role of complement factor H-related protein 5 in venous thromboembolism and COVID-19

A new study discussed the role of complement factor H-related protein 5 (CFHR5) in venous thromboembolism (VTE) patients and hospitalized COVID-19 patients.

25 Apr 2022

Incidence of venous thromboembolism following COVID-19 vaccination

Researchers investigated the association between genetic predisposition to venous thromboembolism and increased risk of thrombosis post-COVID-19 vaccination.

22 Apr 2022

Cancer patients with non-O blood types face higher risk of developing blood clots

A new Blood Advances study suggests that people with cancer and non-O blood types, such as types A, B, and AB, face an increased risk of developing venous thromboembolism (VTE), or blood clots in the veins, three months after their initial diagnosis.

13 Apr 2022

COVID-19 increases risk of bleeding, DVT, and pulmonary embolism

...

11 Apr 2022

Study finds higher risk of thrombotic events after SARS-CoV-2 infection

A study from Sweden published by The BMJ today finds an increased risk of deep vein thrombosis (a blood clot in the leg) up to three months after covid-19 infection, pulmonary embolism (a blood clot in the lung) up to six months, and a bleeding event up to two months.

8 Apr 2022

The effects of severe COVID-19 on the lungs after one year

While short-term lung damage has been reported in patients hospitalized with pneumonia caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is little data on the more chronic sequelae of this condition. A new research paper summarizes data from patients seen one year from discharge.

27 Mar 2022

Clinical determinants of post-COVID-19 thromboembolism

Researchers quantify the risk of acute VTE due to SARS-CoV-2 infection in ambulatory settings.